New Research Indicates Crohn’s Disease and Ulcerative Colitis May Cause Intestinal Damage for Years Before Diagnosis
Biomarkers for Crohn’s Disease and Ulcerative Colitis May Be Present Well Before Symptoms Manifest
A collaborative study between the Francis Crick Institute and Aalborg University has found that blood tests can reveal early indicators of Crohn’s disease up to eight years and ulcerative colitis up to three years before clinical diagnosis.
The research suggests that inflammatory bowel diseases (IBD), including Crohn’s and ulcerative colitis, begin to affect the body far earlier than the emergence of symptoms, potentially opening avenues for preemptive medical intervention or earlier therapeutic treatment.
Although Crohn’s disease and ulcerative colitis are currently incurable and characterized by severe inflammation leading to abdominal pain and other distressing symptoms, early detection and management are crucial for better patient outcomes. It’s common for individuals to experience a significant diagnostic delay, often exceeding a year.
In the latest issue of Cell Reports Medicine, researchers have presented findings from an analysis of Danish electronic health records. They scrutinized the medical data of 20,000 individuals diagnosed with inflammatory bowel disease (IBD) and compared it with a control group extracted from a population of 4.6 million people without IBD.
Previous assumptions held that individuals typically show symptoms approximately a year before receiving an IBD diagnosis, even though extensive intestinal damage at the point of diagnosis indicated a much earlier onset. This study validates such speculations by reviewing a decade’s worth of pre-diagnosis test results, which unveiled early alterations in various blood components, including essential minerals, cell counts, and inflammation indicators like fecal calprotectin.
These early alterations were noted as much as eight years prior to a Crohn’s disease diagnosis and three years before an ulcerative colitis diagnosis. The subtlety of these changes is noteworthy; they were often within the normal ranges in standard blood test results, hence, they would not typically raise alarms. Detecting these patterns required analysis of a large dataset and consideration of a broad array of health markers.
The research team aims to explore whether early interventions could alter the disease course before symptom onset and if these findings might predict future IBD development.
Ph.D. student Marie Vestergaard from Aalborg University and the first author of the study expressed the potential impact of this research on early prediction and treatment strategies, which could significantly enhance life quality for those at risk of IBD.
“I am happy that our research might help predicting who could potentially suffer from IBD and thus start treatment earlier which would greatly improve their quality of life.”
James Lee from the Crick Institute emphasized the importance of this study in understanding the extensive preclinical changes in IBD, indicating a critical period where preventative strategies could be more effective.
“Our research shows that the bowel damage we’re seeing at the point of diagnosis is just the tip of the iceberg. So many changes are subtly taking place in the body before the disease takes hold,” remarked James Lee, Group Leader of the Genetic Mechanisms of Disease Laboratory at the Crick.
The implications for prevention are significant, as the findings reveal a potential period for early intervention. While it’s not yet clear if preventative actions such as dietary modifications or quitting smoking can completely prevent these diseases, the study suggests the potential for such measures. It also emphasizes the critical role of early detection and treatment, considering that numerous gut changes likely occur well in advance of the onset of illness.
Furthermore, Tine Jess from Aalborg University highlighted the innovative nature of the findings, which align with the idea that chronic inflammatory diseases start developing well before diagnosis, underscoring the importance of prevention and early therapeutic intervention.
Crohn’s & Colitis UK CEO Sarah Sleet recognized the value of speeding up diagnoses to improve patient outcomes, noting the challenges posed by long waiting times for tests and reluctance to seek medical advice.
Image Credit: iStock